KING OF PRUSSIA, Pa., May 17, 2011 /PRNewswire/ -- CSL Behring, a global biotherapeutics company specializing in plasma-derived and recombinant therapies and a subsidiary of CSL Limited (ASX: CSL), is a recipient of the National Organization for Rare Disorders (NORD) 2011 Corporate Award. The award was presented this evening at the NORD Partners in Progress Celebration 2011 for "new treatments brought to market for patients with rare diseases."
CSL Behring's new treatment, factor XIII concentrate (human), is approved for the routine prophylactic treatment of congenital factor XIII deficiency, an extremely rare and potentially life-threatening bleeding disorder. Factor XIII concentrate (human) is the first and only dual sub-unit FXIII concentrate. It contains both A and B sub-units to treat FXIII patients regardless of sub-unit deficiency. Congenital factor XIII deficiency is estimated to affect one person in two million, with an incidence in the U.S. of approximately 150 people. (1)
"CSL Behring is honored to receive this NORD Corporate Award," said Paul Perreault, CSL Behring Executive Vice President for Worldwide Commercial Operations and incoming president. "People with rare diseases often face a host of challenges in being accurately diagnosed and in gaining ongoing access to appropriate medical care. CSL Behring focuses on these areas and partners with groups such as NORD to improve patients' lives. We commend NORD for their outstanding achievements and dedication to supporting people with rare diseases."
This award is the most recent in a series of recognitions for CSL Behring's innovative therapies used to treat rare and serious diseases. NORD previously honored CSL Behring for developing fibrinogen concentrate (human) for treating acute bleeding episodes in patients in the U.S. with congenital fibrinogen deficiency (CFD).
NORD is a leading patient advocacy organization whose mission is to advance the causes of people with rare diseases. They provide support for orphan product research – products used to treat serious conditions that affect fewer than 200,000 people – and they develop and advocate on public policy issues before Congress and health agencies.
About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, immune thrombocytopenic purpura, burn treatment and to prevent hemolytic disease of the newborn.
CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX:CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com.
(1) Greenberg C, Sane D, Lai Thung-Shen. Factor XIII and fibrin stabilization. In: Coleman R, Clowes A, Goldhaber S, Marder V, George J, ed. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2006; 325.
Manager Corporate Communications
|SOURCE CSL Behring|
Copyright©2010 PR Newswire.
All rights reserved